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Abstract
Anxiety disorder (AD) is commonly comorbid with other mental illness. It could be a 
state or trait, controversially. Evidence for an association between alcoholism and anxiety 
has emerged from clinical studies of patients with alcoholism, and those of patients with 
anxiety disorders. Alcohol dependence (or abuse) as well as bipolar disorder (BP) is usu-
ally comorbid with anxiety disorder and/or depressive disorder, which often coexist and 
are difficult to distinguish from one another. However, in Han Chinese population, the 
comorbidity rate either with alcoholism or bipolar disorder was not reported as much 
high as reported in Caucasians, this finding of comorbidity between anxiety/depressive 
disorders and alcohol dependence (or abuse) or/and bipolar disorders, possibly at the 
genetic level, makes the differentiation of their categorical diagnoses in the association 
study vitally important.
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1. Introduction
Feinstein [1] started to draw attention on patients with one or more than one diagnosable dis-
ease and defined “Comorbidity” as “any distinct additional clinical entity that has coexisted or that 
may occur during the clinical course of a patient who has the index disease under study.” In the major-
ity of studies, comorbidity refers to the co-occurrence of at least two different disorders in the 
same individual. Although the majority of comorbidity research has been at the diagnostic 
(or syndrome) level (i.e., the presence of co-occurring DSM-IV disorders); another approach 
is to study the extent to which certain symptoms or symptom patterns tend to co-occur [2–5].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Regardless of types of anxiety disorder (AD), anxiety is one of the most prevalent of all psy-
chiatric disorders in other mental illnesses, such as mood disorders and alcoholism. Different 
types of mental illnesses commonly comorbid with AD as well as the ethnic role will be 
reviewed. The comorbidity has gained increasing prominence in psychiatry and psychology 
in the past few decades [6]. A distinction between two types of comorbidity has been drawn 
a decade ago by Angold et al. [7].
Reiger et al. [8] reported that approximately 15% of people suffered from AD, according to 
Diagnostic and Statistical Manual-3rd edition (DSM-III) during their lifetime. Keith et al. (1991) 
compared the prevalence of AD, including subtypes between community and the institute 
prevalence rates, and found the lifetime rate of AD was 15% overall, 16% in nursing home 
residents, 28% in prisoners, and 51% in patients in mental hospitals. Further, Robins et al. 
[9] studied the prevalence of AD and found that phobia is the most common AD (Figure 1).
As the more specific and classified the AD was studied, simple phobia was reported as the 
most common comorbidity, up to nearly 50%. Approximately 13% of people reported symp-
toms matching the DSM criteria, and social anxiety disorder was in the second place of highest 
reported disorder of anxiety. Post-traumatic stress disorder (PTSD), often goes unrecognized, 
but its prevalence reached 20% in victims of war trauma.
However, the more commonly recognized disorders, such as generalized anxiety disorder 
(GAD) and panic disorder (PD), have the lower lifetime prevalence rates of approximately 5 and 
3.5%, respectively. Another often underdiagnosed disorder, obsession-compulsive disorder 
(OCD), is found in 2.5% of the population. Interestingly, a recent study found very little change 
in the prevalence of mental disorders, including specific anxiety disorders, since 1990 [10].
Because of high recognition and high prevalence rate, researchers started to explore whether 
AD is a genetic-related psychiatric disorder. Therefore, genetic risk factors are being studied; 
researchers have found genetic predisposition for two broad groups of anxiety disorders: a 
panic-generalized anxiety-agoraphobia group and a specific phobia group [11]. More clini-
cally important risk factors include comorbid substance abuse and family history. Weissman 
et al. [12] conducted a 20-year study in the offspring of depressed parents and found a three-
fold increase in ADs, including greater substance abuse, younger onset, and more significant 
physical health concerns.
Although a genetic predisposition for developing an AD is likely [11], environmental stress-
ors clearly play a role in varying degrees. All of the disorders are affected in some way by 
Figure 1. Robins et al. [9] studied in the prevalence of subtypes of AD.
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external cues and how they are proceeded and reacted to. Research has also shown that 
patients suffering from anxiety are generally more sensitive to physiologic changes than non-
anxious patients, and panic disorder sufferers are even more sensitive to these than the GAD 
patients. Objective testing, however, reveals that physiologic changes between anxious and 
nonanxious patients are comparable. This heightened sensitivity leads to diminished auto-
nomic flexibility, which may be the result of faulty central information processing in anxiety-
prone persons [13].
The neuroanatomical foundation of anxiety may be related to the influence of the septohippo-
campal system in the brain on learning and memory [14]. Patients with AD manifest impaired 
divided attention [15], verbal learning, verbal recall [16], visual learning and memory [17], 
episodic memory and executive function [18], and cognitive information processing [19].
2. Anxiety disorder as comorbidity
2.1. Anxiety disorder as comorbidity in bipolar disorders
Prior to year 2000, there were few studies on bipolar disorder II (BPII) and little research into 
the differences between BPI and BPII patients. More and more studies have been conducted 
to distinguish between the subdivisions of bipolar disorders (BPI and BPII). Genetically, there 
was an association with the interaction between COMT and DRD3 gene in BPI [20] as well as 
the interaction between DRD2/ANKK1 and the ALDH2 gene in BPII patients [21]. A statisti-
cally significant, main effect for the Met/Met genotype of the COMT Val158Met polymor-
phism and a significant interaction effect for the Met/Met genotype of the COMT Val158Met 
and Ser/Ser genotypes of the DRD3 Ser9Gly polymorphism could predict BPI, but not BPII 
compared to normal subjects [20]. Moreover, Lee et al. [22] provided evidence that the ALDH2 
and 5-HT2A genes interact in BPI but not in BPII. A series of studies have been conducted to 
prove that BPI and BPII are different from genetic aspect.
Anxiety disorders have been reported as a common comorbidity in BP [23–28], the life time 
prevalence was reported by National Institute of Mental Health (NIMH) as 51.2% [29, 30], and 
current anxiety disorders in 31% of the first 500 patients enrolled in the Systematic Treatment 
Enhancement Program for Bipolar Disorder (STEP-BD) [30]. The National Comorbidity Survey 
reports that approximately 90% (BPI: 86–92%; BPII: 89%) of bipolar patients comorbid with 
AD [31–33]. More often, comorbid with panic disorder (PD), post-traumatic stress disorder 
(PTSD), and obsessive-compulsive disorder (OCD) either in the community or in primary care 
and psychiatric settings has been reported [30, 32, 34, 35]. There is a growing body of research 
evidence that bipolar depressives have comparable if not higher rates of comorbid anxiety dis-
orders than unipolar depressives [23, 24, 26–28, 36]. Accordingly, anxiety comorbidity could 
be a fundamental feature of bipolar disorder [37]. Recent studies reported that among all bipo-
lar disorders, BPII has higher comorbidity with AD than does BPI [23, 25, 26, 28, 38].
Other important aspects to be borne in mind are recognition and prognosis. Compared to 
noncomorbid BP, BP patients with AD are susceptible to a higher risk of suicidal behav-
ior [39], substance abuse [30, 40, 41], lower psychosocial performance [29] and has a more 
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 frequent family history of mental illness [42]. Moreover, the AD comorbidity can complicate 
the course of illness and pharmacological treatment strategies [43]. Not only the high comor-
bidity between BP and AD has been noticed, but the types of AD comorbidity in BP could also 
complicate the recognition of BPI and BPII and predict the prognosis. Patients with BP and 
AD are susceptible to higher risk of suicidal behaviour [39], substance abuse [30, 40, 41], lower 
psychosocial performance [29], and a more frequent family history of mental illness than BP 
patients without AD [42]. Moreover, the AD comorbidity would complicate the course of ill-
ness and pharmacological treatment strategies [43].
A number of studies [23–26, 44] have shown bipolar disorder to be highly comorbid with 
anxiety disorder; a prevalent rate of 51.2% was reported by the National Institute of Mental 
Health (NIMH) [30, 45]. BP is most frequently associated with panic disorder (PD), post-trau-
matic stress disorder (PTSD), and obsessive-compulsive disorder (OCD), whether in the com-
munity, in primary care, or in psychiatric settings [30, 32, 34, 35]. The National Comorbidity 
Survey reports that approximately 90% of BP patients (BP-I: 86–92%; BP-II: 89%) have at least 
one comorbid AD [31–33].
There is a growing body of research evidence that individuals with bipolar depression have 
comparable if not higher rates of comorbid ADs than do individuals with unipolar depression 
[23, 24, 26, 27, 36, 44]. Anxiety comorbidity is, then, a fundamental feature of BP [37]. Moreover, 
established studies [23, 25, 26, 38, 44] show that BP-II is more often comorbid with AD than 
is BPI. The BP patients with AD comorbidity have been pointed out to have worse prognosis, 
such as shortened euthymia, delayed remission, and rapid cycling. The AD comorbidity wors-
ens BP patients’ episode and their response to treatment, and increases their suicidal behavior. 
Previous researchers have also pointed out a higher possibility of comorbidity with substance 
use disorder in BP patient comorbid with AD (BP+AD) than in BP without AD (BP−AD) [30, 
34, 46–54]. Consequently, the comorbidity with AD receives more attention clinically [55, 56].
2.2. Anxiety disorder as comorbidity in bipolar disorders of ethnics
Chang et al. [57] found that the anxiety disorder comorbidity rate in both BPI (26.7%) and BPII 
(39.0%) were lower in Han Chinese in Taiwan than in Western populations (more than 50% in 
BPI and BPII) [26, 30]. There was no significant difference in the gender-based distribution of 
anxiety disorder in our patients, which agrees with one study [58] but disagrees with others 
[34, 59, 60] that report a higher prevalence in women than in men. One reason may be that 
lower prevalence of a disease shows a greater statistical meaning for fixed heritability and 
a fixed number of trait loci [61]. Therefore, the lower anxiety disorder comorbidity rate not 
only is more easy for researchers to look at the genetic factor of AD high comorbid with BP 
but also may decrease psychosocial, cultural, and other confounding factors. Those factors 
and their interaction might increase the prevalence rate of mental illness, especially anxiety 
disorder. In addition, a higher comorbidity rate with BPII than with BPI was found which 
agreed with most of large-sample epidemiological studies [23, 25, 26, 28, 38]. Patients with 
BP and co-occurring anxiety symptoms or anxiety disorders are susceptible to higher rates 
of depressive episodes [29], which may explain the higher comorbidity rate in patients with 
BPII than with BPI.
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For further investigation of the AD subtypes with BP, Chang et al. [57] found that the highest 
AD comorbidity in both subtypes of BP patients was GAD instead of PD or OCD, the major 
AD comorbidities in the western BP populations. Wittchen et al. [62] reported that the highest 
rate of comorbidity of GAD was associated with major depressive disorder (62.4%) and the 
lowest with BP (10.5%). One of the possible reasons may be due to ethnic differences or the 
genetic heterogeneity of anxiety disorder and depressive disorder like BPII. A higher occur-
rence of GAD with BPII was found in Chang et al. (2012)’s study, which is similar to previous 
studies showing higher occurrence of GAD with MDD [63, 64]. This gender difference in BPII 
could be derived from the high GAD-associated depression. However, the causal relationship 
should be further investigated. The other reason could be that the same diagnostic criteria of 
BPI and BPII except the duration might not be appropriate, the redefinition of the diagnostic 
criteria after more different ethnic BP subtype studies are suggested.
Chang et al. [57] have reported a relatively low rate of anxiety-disorder comorbidity in both 
BP subtypes in Han Chinese population in Taiwan, implying an ethnic possibility. Because of 
this low anxiety-disorder comorbidity in BP population in Taiwan, it was easier to identify BP 
patients with/without comorbidities to study the influence of anxiety-disorder comorbidity 
on neuropsychiatric performance. Although causal relationship between the comorbid anxi-
ety disorders in BPI and BPII is not yet clear, additional studies are required, and the ethnic 
differences are suggested to be taken into account.
BPII patients with anxiety-disorder comorbidity also showed more substance abuse and 
dependence, suicide attempts, and personality disorders than did BPI patients [23, 25, 26, 28, 
30, 57, 65]. After excluding the comorbidity of anxiety disorder, BPI and BPII patients have 
similar suicide rates, suggesting that AD comorbidity increases the risk of suicide in BPII 
[66]. The risk of suicide in Han Chinese BP patients in Taiwan may be lower than western BP 
populations, but it needs further study to confirm.
Anxiety disorders occur most frequently during depressive episodes in patients with BP [67], 
except for those in the depressive state, anxiety disorder would often present during sub-
syndromal states [68]. Boylan et al. [49] reported that about 32% of their BP patients had 
more than two comorbid anxiety disorders. The lower incidence in BPI patients (21.9%) and 
a similar incidence in BPII patients (33.8%) were found. This finding implies that BP patients 
with multiple anxiety-disorder comorbidities may have a more severe psychopathology and 
a worse prognosis, even with what is currently considered as appropriate treatment [69]. In 
addition, anxiety disorder may be a predisposing factor for BP. Long-term follow-up studies 
are needed to confirm whether some anxiety-disorder comorbidities are in remission during 
the inter-episode stage or increase in intensity as symptoms of depression worsen.
2.3 Genetic aspect in comorbidity with anxiety disorder in bipolar disorders
Relative genetic factor between BP and AD was proposed [70], but no definite susceptibility 
gene for BP has been identified. One possible explanation could be neither subtypes of BP nor 
comorbidities were differentiated in most studies [71–73]. The contribution of genetic factors 
to the etiology of BP has also been reported from studies on family, twin, and adoption [72, 
74]. From the twin studies, the inheritance for bipolar disorder overall is around 85% [75, 76]. 
Comorbid Mental Disorders in Anxiety Disorders: Genetic Aspects of Bipolar Disorders and of Ethnicity
http://dx.doi.org/10.5772/66117
69
The distinction between BPI and BPII may be associated with different genetic categories [21, 
77–79]. Knowing the association between AD comorbidity and BP at the genetic level may 
improve our understanding more in this mental illness.
Dopaminergic dysfunction has been implicated in the pathogenesis of bipolar disorder, espe-
cially the dopamine D2 receptor gene (DRD2) on chromosome 11q22.3, and dopamine D3 
receptor gene (DRD3) on chromosome 3q13.3, expressed exclusively in the limbic regions 
of the brain responsible for controlling emotions and behavior as well as cognition [80, 81]. 
The DRD2 Taq-IA (rs1800497) restriction in fragment length of polymorphism is linked to the 
density of dopamine D2 receptors [82]. A variety of studies have analyzed dopamine recep-
tor genes for their associations with BP or AD, including polymorphisms in DRD2 [83, 84]. 
The DRD3 gene is encoded as a target site for antipsychotic agents, which are efficient in the 
treatment of this disorder. The most frequently studied allele variation of the DRD3 gene is 
the DRD3 Ser9Gly polymorphism (rs6280) [85], causing a serine- (Ser) to-glycine (Gly) substi-
tution and a significantly increased dopamine binding affinity [86]. The Gly9 allele is associ-
ated with significantly greater odds for treatment response to antipsychotics [87, 88]. Possible 
association between the DRD2 gene, DRD3 gene, and bipolar disorder has been reported in 
a family-based study [89] but not in others [83, 84, 90, 91]. Therefore, the DRD2 and DRD3 
genes are of particular interest in the study of susceptibility to bipolar disorder because both 
effective episodes and neurocognitive impairments are important aspects of BP [92] and AD.
In the midbrain-hindbrain regions, another important role in the development of dopaminer-
gic neuron, brain-derived neurotrophic factor (BDNF), in which the BDNF gene was selec-
tively deleted, the number of tyrosine hydroxylase-expressing dopaminergic neurons was 
found reduced [93]. During the developing years and in adulthood, BDNF gene encoded on 
human chromosome 11p13 was shown to regulate the expression of DRD3 in the nucleus 
accumbens [94]. The involvement of BDNF in the pathogenesis of mood disorders and the 
mechanism of mood stabilizing medication has been suggested [95]. Genetic studies explored 
the potential association between BDNF gene variants and bipolar disorders yet yield con-
flicting results. The most investigated BDNF gene is Val66Met (rs6265) with functional con-
sequences from valine (Val) to methionine (Met) at codon 66 [95–98]. The Met allele has been 
pointed out to have association with impairments in intracellular trafficking and activity-
dependent secretion of BDNF in neurons [95–98]. A significant association between Val66Met 
and bipolar disorder has also been reported in several studies conducted in North American 
and European populations [100–103] with overtransmission of the Val allele while other stud-
ies in the Asian populations were not [99–101]. About 80% with Val allele was reported in the 
European population while only 50% was reported in Asian [102], the ethnic difference could 
be the possibility.
2.4. The DRD2 gene associated with ALDH2 in bipolar II disorder with anxiety disorder
There is an increased risk of mental disorder among relatives of anxiety neurotics from family 
studies [103]. Therefore, if the DRD2 locus is linked to a predisposition to conduct AD and BP, 
its relation with anxiety disorder and BP is worth further examination. Knutson et al. [104] 
proposed molecular explanation that a low serotonin turnover rate and aggressive behavior 
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are mediated by negative emotions such as insecurity and anxiety. Some studies also suggest 
that conduct disorder might lead to alcoholism because of the tendency for a person to be 
impulsive [105] and to exhibit behavior disinhibition [106]. Besides the association of DRD2 
gene with anxiety and mood regulation, we also set forth to determine the possible relation-
ship with DRD2 in AD and BP to examine any association between DRD2 and other possible 
genetics.
Brain-imaging study [82] shows that healthy controls with an A1 allele of the DRD2 TaqIA 
gene have fewer DRD2 receptors than those without the A1 allele. Individuals with at least 
one A1 allele appear to have up to 40% fewer striatal DRD2 receptors than those carrying the 
A2/A2 allele [107]. The DRD2 TaqIA A1 allele was associated with fewer DRD2s in the stria-
tum and hence, a lower dopaminergic function.
Enzymes that function in the metabolic breakdown of acetaldehyde are considered as the 
ALDH2 gene; the enzyme functioning in the metabolic process of acetaldehyde is majorly 
influencing drinking behavior and the development of alcoholism. The ALDH2 shows 
two variant alleles: ALDH2*1 and ALDH2*2. The ALDH2*1/*1-encoded enzyme is active 
in the metabolism of acetaldehyde, whereas the enzymes encoded by the ALDH2*1/*2 and 
ALDH2*2/*2 are partially and totally inactive, respectively. It is believed that the ALDH2*2 
allele, with reduced enzyme activity, provides protection against the risk of developing alco-
holism [108]. In previous reports, nearly half of the East Asian population has the ALDH2*2 
allele variant [109], including Han Chinese in Taiwan [108, 110], but this allele is rarely found 
in other ethnic populations.
Wang et al. [111] revealed the relationship among DRD2 gene and ALDH2 gene between BP 
with and without AD and found, we examined whether the DRD2 and ALDH2 genes were 
associated with comorbid BP-II and AD. The study results revealed the significant associa-
tion of DRD2 Taq-IA A1/A2 in the BP-II with AD and the significant interaction between the 
ALDH2 and DRD2 genes in BP-II without AD, respectively. Our findings provide genetic 
evidence to support the hypothesis that BPII with or without AD might be two distinct mental 
illnesses [112, 113]. Such interaction also implies the complex role of dopamine system in the 
pathogenesis of BPII.
2.5. The DRD3 gene and BDNF gene associated with bipolar subtypes with/out anxiety 
disorder
Chang et al. [114] investigated the association between DRD3 gene and BDNF gene in bipolar 
subtypes comorbid with/without AD. They found a significant main effect of the Ser/Gly of 
the DRD3 Ser9Gly polymorphism in BPII+AD, and interaction with the BDNF Val66Met Met/
Val genotype and indicated a possible mediator by the BDNF Val66Met Val/Val genotype in 
the development to the AD comorbidity in the BPII. The involvement of the DRD3 Ser9Gly 
Ser/Gly genotype disagrees with the previous studies of the risk to develop anxiety disorders, 
such as obsessive compulsive personality (OCD) [115, 116]. This difference may reflect the 
report that in Han Chinese, the most AD subtype comorbidity in BP subtypes is generalized 
anxiety disorder [57] instead of OCD or panic disorder mostly reported in the western popu-
lation [6]. Further investigation between ethnics should be considered.
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Takahashi et al. [117] has reported the effect of the DRD3 and BDNF variation on brain mor-
phology in midline and medial temporal lobe structures in healthy controls. Gourion et al. 
[118] earlier has reported that this interaction was associated with earlier emergence of psy-
chosis in schizophrenia patients. The involvement of abnormal dopamine regulation in bipo-
lar disorders have been reported in gene-gene interaction study; however, this interaction is 
associated with treatment response of dopamine receptor antagonists for bipolar disorders or 
previous psychotic symptoms may require further studies with additional characterization 
and phenotyping.
There have been some reports about that the Met heterozygotes compared to the Val homozy-
gotes of the BDNF Val66Met polymorphism have impairment in intracellular trafficking and 
activity-dependent secretion of BDNF in neurons [95–98]. In addition, the Ser heterozygotes 
compared to the Gly homozygotes of the DRD3 Sere9Gly polymorphism were reported to 
decrease the dopamine binding affinity [86]. Odds for BPII+AD were higher for those BDNF 
Met66Val Met/Met and Met/Val with the interaction of the DRD3 Ser9Gly Ser/Gly genotype 
compared to those with Gly/Gly genotypes.
For the results in the BPI, a main effect of BDNF Met/Val genotype was found to be associated 
with BPI−AD, and an interaction was found between BDNF Met/Val with DRD3 Ser9Gly Ser/Ser 
genotype in BPI−AD. From the results in both subtypes, it implies the different involvement of 
DRD3 and BDNF genetic variants between two subtypes of the BP, and the variation of neuropsy-
chological performance [119]. No case with the DRD3 Ser9Gly Gly/Gly genotype was reported 
in the BPI−AD, and impact of the AD comorbidity on the BPI impaired their executive function 
and attention, while psychomotor speed, working memory, and visual immediate memory was 
impaired in the BPII [119], implying the different roles of the DRD3 Ser9Gly polymorphisms.
Chang et al. [114] have provided initial evidence of the involvement of dopaminergic path-
way with DRD3 Ser9Gly gene in the pathogenesis of bipolar disorder. For the results in the 
BPI, a main effect of BDNF Met/Val genotype was found to be associated with BPI−AD, and an 
interaction was found between BDNF Met/Val with DRD3 Ser9Gly Ser/Ser genotype in BPI−AD. 
From the results in both subtypes, it implies the different involvement of DRD3 and BDNF 
genetic variants between two subtypes of the BP, and the variation of neuropsychological per-
formance [119]. No case with the DRD3 Ser9Gly Gly/Gly genotype was reported in the BPI−AD, 
and impact of the AD comorbidity on the BPI impaired their executive function and attention, 
while psychomotor speed, working memory, and visual immediate memory was impaired in 
BPII [119], implying the different roles of the DRD3 Ser9Gly polymorphisms.
The results in Chang et al.’s study [114] not only replicated Lohoff et al. [120] finding that the 
positive association was between the Val allele and the BPI patients, but also related to the AD 
comorbidity. However, a disagreement was noticed between this study and previous findings 
of association between the Met allele with anxiety disorders [121, 122], indicating the possible 
ethnic variation. Moreover, the major subtype of AD comorbidity in the Han Chinese BPI and 
BPII was general anxiety disorder [57] while PD or OCD was the higher comorbidity with the 
BP in the western population [30, 32, 34, 35]. The genotype distribution of the BDNF Val66Met 
polymorphism in current study is consistent with other Asian populations, but different from 
European populations [102].
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3. Anxiety disorder as comorbidity in alcoholism of ethnics
3.1. The relationship between DRD2 gene and ALDH2 gene in anxiety-depression 
alcoholism
Several studies in alcohol detoxification have been reported that the DRD2 gene may be 
associated with high scores of anxiety and depression in alcohol dependence. Patients with 
alcohol dependence comorbid with anxiety and/or depressive disorders represented the 
greatest risk of relapse [123–125]. In a double-blind treatment study using bromocriptine, 
ALC individuals with DRD2 A1 allele showed the greatest improvement in craving and anxi-
ety [126]. These observations are in agreement of an association between DRD2 gene and 
anxiety-depressive alcohol dependence (or abuse). To elucidate the association between the 
DRD2 gene and alcohol dependence in Han Chinese population with attempts to overcome 
the possible confounding effects and to reduce false-positive or -negative results, Huang et 
al. [127] compared individuals with solely anxiety-depression (ANX/DEP), individuals with 
both alcohol dependence and anxiety-depression (ANX/DEP ALC), and individuals with 
pure alcohol dependence and normal controls. Strong linkage disequilibrium between the 
TaqI A and B polymorphisms of the DRD2 gene was reported. Huang et al. [127] found that 
the frequency of the A1/B1 haplotype was significantly higher in the ANX/DEP ALC group 
than that of controls. There was no association between the DRD2 haplotype and pure alcohol 
dependence or ANX/DEP when compared to controls.
Since ALDH2 is a crucial enzyme for ethanol catabolism which might also play an important 
role in dopamine catabolism and risk for alcoholism, the involvement of the ALDH2 gene 
with the association of the DRD2 gene and ANX/DEP ALC was further investigated. It was 
shown that the DRD2 gene is associated with ANX/DEP ALC only after controlling for the 
ALDH2*1/*1 genotype, supporting the contention that the DRD2 gene may interact with the 
ALDH2 genes in ANX/DEP ALC.
3.2. Interaction between personality traits and genes in anxiety-depressive alcoholism
Cloninger has hypothesized of lower novelty seeking and higher harm avoidance in type 
I alcoholism compared with healthy volunteers. Later, Huang et al. [127] and Huang et al. 
[128] have proved that anxiety-depressive alcohol dependence (ANX/DEPALC) could be 
a genetically well-defined subtype of alcoholism linking to DRD2. Similar clinical char-
acteristics with Type I alcoholism has been found in the ANX/DEPALC with late-onset 
and more anxious/depressed traits, and their suffering from anxiety/depression related 
to heavy drinking. The higher NS and HA scores were found in the ANX/DEPALC than 
in the pure ALC. This result might indicate that ANX/DEP ALC belongs to a subtype of 
alcoholism [127]. Furthermore, an association was found between ANX/DEP ALC and NS, 
but only in subjects with DRD2 TaqIA A1+ allele (including A1/A1 or A1/A2 genotype). 
In addition, the difference in NS between ANX/DEP ALC and Pure ALC existed in sub-
jects with S/S genotype of 5-HTTLPR. The potential genes, DRD2 TaqIA A1+ allele and 
5-HTTLPR may involve in the development of ANX/DEP ALC with novelty seeking per-
sonality trait [127].
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Further analysis with stratification of the DRD2 TaqIA A1/A1 or A1/A2 genotype subjects, the 
difference in NS scores was only found in subjects with 5-HTTLPR S/S genotype. The ANX/
DEPALC was associated with HA only in subjects with 5-HTTLPR S/L and L/L genotypes, sug-
gesting that the personality traits of type I alcoholism in Cloninger’s model might need modi-
fication. The 5-HTTLPR polymorphism involved in both NS and HA implied that personality 
traits related to multiple genes could be possible in developing mental disorder. Therefore, 
multiple genes would be suggested to be considered in the further study .
4. Summary
Wang et al. [111] provided preliminary evidence that comorbid BP-II+AD might be one of the 
subtypes of BPII. The DRD2 gene could be an important candidate gene for the comorbidity 
of AD in other mental illness and ALDH2 gene might moderate the impact of DRD2 gene on 
BPII with or without AD. Moreover, Chang et al. [114] revealed the exact effect of this interac-
tion on DRD3 binding affinity and neuron secretion of BDNF is not clear yet may be associ-
ated with the pathogenesis of anxiety disorders. The Gly/Gly genotypes of the DRD3 Ser9Gly 
have been associated with unipolar depression [129]; this might explain the main effect was 
only found in the BPII+AD but not in the BPI+AD. A possibility could be ethnic differences or the 
genetic heterogeneity of AD and depressive disorder like BPII; because in the Han Chinese, 
GAD has been reported as the major AD comorbidity in the BPII [57] while it was reported 
to be associated with major depression in other ethnics [64, 130]. In addition, ADs occur most 
frequently during depressive and depressive manic episodes in BP patients [67] as well as 
during subsyndromal depressive states [68]. Since long-term follow-ups have shown that 
patients with BPII have a more chronic course, more mood episodes, more major and minor 
depressive episodes which last longer than those of patients with BPI [131–133], whether the 
interaction between the BDNF and DRD3 genes is related to the clinical characteristics of 
BPII+AD, for example, depression-proneness, may still require further study.
Previous studies provided initial evidence of the involvement of dopaminergic pathway as 
well as serotonin system in the pathogenesis of bipolar disorder [110, 113, 134, 135]. However, 
whether the interaction of these genes leads to dysfunctional dopaminergic signaling or sero-
tonin regulation and to what extent these genes would affect the etiology of bipolar disor-
der with AD comorbidity still require further clarification. Moreover, AD playing the role of 
comorbidity in BP and alcoholism showed relatively lower prevalence rate in Han Chinese 
while compared to previous studies conducted in Western population. This finding implied 
an ethnic possibility which has been supported in some studies with genetic investigation. 
Moreover, in both BP and ALC with AD comorbidity have been reported to have relationship 
with dopaminergic genes as well as serotonin-related genes, the ALDH2 gene plays the most 
important role in both disorders with AD comorbidity. The frequency of ALDH2 gene has 
been found differently in Han Chinese compared to Caucasians, further causal-relationship 
investigation of this gene in AD comorbidity is needed to confirm.
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